Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 2, 2023
- First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperative PRMT5 inhibitor, in Amgen-sponsored Phase 1/2 clinical trial - Global...
-
Aug 1, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming...
-
Jul 28, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 27, 2023, the...
-
Jun 30, 2023
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 29, 2023, the...
-
Jun 22, 2023
Eye preservation reported for the first UM patient treated with darovasertib monotherapy under the amended IST protocol enabling neoadjuvant treatment up to 6 months Patient experience shared in...
